BioNTech and Pfizer Announce Nature Publication of German Phase 1/2 Study Data from mRNA-based Vaccine Candidate BNT162b1 Against SARS-CoV-2

MAINZ, GERMANY and NEW YORK, September 30, 2020 — BioNTech SE (Nasdaq: BNTX) and Pfizer Inc. (NYSE: PFE) today announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2 Study of BNT162b1 were...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials